Key points are not available for this paper at this time.
engineering. Despite this promise, challenges remain, including cell-specific targeting, control of transgene persistence, immunogenicity, and regulatory considerations. Together, these innovations signal a paradigm shift in the generation and deployment of CAR-based cellular immunotherapies.
Rallis et al. (Fri,) studied this question.